Prostatype Financial Statements From 2010 to 2024
| PROGEN Stock | SEK 7.50 0.15 1.96% |
Check Prostatype Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prostatype Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Prostatype financial statements analysis is a perfect complement when working with Prostatype Genomics Valuation or Volatility modules.
Prostatype |
Prostatype Genomics AB Company Return On Equity Analysis
Prostatype Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Prostatype Genomics Return On Equity | -0.7 |
Most of Prostatype Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prostatype Genomics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Prostatype Genomics AB has a Return On Equity of -0.7024. This is 97.07% lower than that of the Healthcare sector and 89.49% lower than that of the Diagnostics & Research industry. The return on equity for all Sweden stocks is 126.58% higher than that of the company.
Prostatype Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prostatype Genomics competition to find correlations between indicators driving Prostatype Genomics's intrinsic value. More Info.Prostatype Genomics AB is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Prostatype Genomics Financial Statements
Prostatype Genomics stakeholders use historical fundamental indicators, such as Prostatype Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Prostatype Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prostatype Genomics' assets and liabilities are reflected in the revenues and expenses on Prostatype Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prostatype Genomics AB. Please read more on our technical analysis and fundamental analysis pages.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.